Browse Studies — Arctuva | Arctuva

Browse Studies About FAQ

Sign in Get started

Browse studies

Find your next paid study

1 recruiting study matching your filters

Newest first Highest paying

Filters

Condition

Location

Phase

Min compensation ($)

Max compensation ($)

RASolute 304: A Phase 3 Multicenter, Open-label, Randomized, 2-Arm Study of Adjuvant Daraxonrasib Versus Standard of Care Observation Following Completion of Neoadjuvant and/or Adjuvant Chemotherapy in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

The purpose of this study is to evaluate the safety and efficacy of a novel RAS(ON) inhibitor compared to standard of care (SOC) observation only.

Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma+2 more

Revolution Medicines, Inc.NCT07252232

Arctuva

Connecting verified participants with clinical studies that matter.

Platform

Browse Studies
Join Arctuva
My Profile

Company

About
FAQ

Legal

Privacy Policy
Terms of Service

© 2026 Arctuva. All rights reserved.